The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
RET fusions in solid tumors
Abstract
The RET proto-oncogene has been well-studied. RET is involved in many different physiological and developmental functions. When altered, RET mutations influence disease in a variety of organ systems from Hirschsprung's disease and multiple endocrine neoplasia 2 (MEN2) to papillary thyroid carcinoma (PTC) and non-small cell lung cancer (NSCLC). Changes in RET expression have been discovered in 30-70% of invasive breast cancers and 50-60% of pancreatic ductal adenocarcinomas in addition to colorectal adenocarcinoma, melanoma, small cell lung cancer, neuroblastoma, and small intestine neuroendocrine tumors. RET mutations have been associated with tumor proliferation, invasion, and migration. RET fusions or rearrangements are somatic juxtapositions of 5' sequences from other genes with 3' RET sequences encoding tyrosine kinase. RET rearrangements occur in approximately 2.5-73% of sporadic PTC and 1-3% of NSCLC patients. The most common RET fusions are CDCC6-RET and NCOA4-RET in PTC and KIF5B-RET in NSCLC. Tyrosine kinase inhibitors are drugs that target kinases such as RET in RET-driven (RET-mutation or RET-fusion-positive) disease. Multikinase inhibitors (MKI) target various kinases and other receptors. Several MKIs are FDA-approved for cancer therapy (sunitinib, sorafenib, vandetanib, cabozantinib, regorafenib, ponatinib, lenvatinib, alectinib) and non-oncologic disease (nintedanib). Selective RET inhibitor drugs LOXO-292 (selpercatinib) and BLU-667 (pralsetinib) are also undergoing phase I/II and I clinical trials, respectively, with preliminary results demonstrating partial response and low incidence of serious adverse events. RET fusions provide a viable therapeutic target for oncologic treatment, and further study is warranted into the prevalence and pathogenesis of RET fusions as well as development of current and new tyrosine kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Agrawal, N., Akbani, R., Aksoy, B. A., Ally, A., Arachchi, H., Asa, S. L., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.050 · Cited by 3,062
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
RET, ROS1 and ALK fusions in lung cancer
Takeuchi, K., Soda, M., Togashi, Y., Suzuki, R., Sakata, S., Hatano, S., Asaka, R., Hamanaka, W., Ninomiya, H., Uehara, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2658 · Cited by 1,320
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Hirschsprung disease, associated syndromes and genetics: a review
Amiel, J., Sproat-Emison, E., Garcia-Barcelo, M., Lantieri, F., Burzynski, G., Borrego, S., Pelet, A., Arnold, S., Miao, X., Griseri, P., et al. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.053959 · Cited by 1,206
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Anchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 915
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom, T., Brennan, K. W., et al. (2012) · Nature Medicine · doi:10.1038/nm.2673 · Cited by 869
Activation of a novel human transforming gene, ret, by DNA rearrangement
Takahashi, M., Ritz, J., & Cooper, G. M. (1985) · Cell · doi:10.1016/0092-8674(85)90115-1 · Cited by 854
KIF5B-RET fusions in lung adenocarcinoma
Kohno, T., Ichikawa, H., Totoki, Y., Yasuda, K., Hiramoto, M., Nammo, T., Sakamoto, H., Tsuta, K., Furuta, K., Shimada, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2644 · Cited by 834
Mutations of the RET proto-oncogene in Hirschsprung's disease
Edery, P., Lyonnet, S., Mulligan, L. M., Pelet, A., Dow, E., Abel, L., Holder, S., Nihoul-Fékété, C., Ponder, B. A. J., & Munnich, A. (1994) · Nature · doi:10.1038/367378a0 · Cited by 749
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 717
Romeo, G., Ronchetto, P., Luo, Y., Barone, V., Seri, M., Ceccherini, I., Pasini, B., Bocciardi, R., Lerone, M., Kääriäinen, H., et al. (1994) · Nature · doi:10.1038/367377a0 · Cited by 700
Nikiforov, Y. E., Rowland, J. M., Bove, K. E., Monforte-Muñoz, H., & Fagin, J. A. (1997) · PubMed · Cited by 666
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Rolfo, C., Mack, P. C., Scagliotti, G. V., Baas, P., Barlesi, F., Bivona, T. G., Herbst, R. S., Mok, T. S., Peled, N., Pirker, R., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.030 · Cited by 660
Self-citationRET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
Wang, R., Hu, H., Pan, Y., Li, Y., Ye, T., Li, C., Luo, X., Wang, L., Li, H., Zhang, Y., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.1477 · Cited by 546
RET revisited: expanding the oncogenic portfolio
Mulligan, L. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3680 · Cited by 513
RET/PTC Rearrangement in Thyroid Tumors
Nikiforov, Y. E. (2002) · Endocrine Pathology · doi:10.1385/ep:13:1:03 · Cited by 489
Ju, Y. S., Lee, W.-C., Shin, J.-Y., Lee, S., Bleazard, T., Won, J.-K., Kim, Y. T., Kim, J.-I., Kang, J.-H., & Seo, J.-S. (2012) · Genome Research · doi:10.1101/gr.133645.111 · Cited by 484
Drilon, A., Rekhtman, N., Arcila, M., Wang, L., Ni, A., Albano, M., Van Voorthuysen, M., Somwar, R., Smith, R. S., Montecalvo, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30562-9 · Cited by 484
Benayed, R., Offin, M., Mullaney, K., Sukhadia, P., Rios, K., Desmeules, P., Ptashkin, R., Won, H., Chang, J., Halpenny, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0225 · Cited by 484
RET tyrosine kinase signaling in development and cancer
Arighi, E., Borrello, M. G., & Sariola, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.010 · Cited by 468
Piotrowska, Z., Isozaki, H., Lennerz, J. K., Gainor, J. F., Lennes, I. T., Zhu, V. W., Marcoux, N., Banwait, M. K., Digumarthy, S. R., Su, W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1022 · Cited by 442
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Subbiah, V., Gainor, J. F., Rahal, R., Brubaker, J. D., Kim, J. L., Maynard, M., Hu, W., Cao, Q., Sheets, M. P., Wilson, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0338 · Cited by 396
Gautschi, O., Milia, J., Filleron, T., Wolf, J., Carbone, D. P., Owen, D., Camidge, R., Narayanan, V., Doebele, R. C., Besse, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.9352 · Cited by 360
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
Romei, C., Ciampi, R., & Elisei, R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.11 · Cited by 352
Bounacer, A., Wicker, R., Caillou, B., Cailleux, A. F., Sarasin, A., Schlumberger, M., & Suárez, H. G. (1997) · Oncogene · doi:10.1038/sj.onc.1200206 · Cited by 339
Tansey, M. G., Baloh, R. H., Milbrandt, J., & Johnson, E. M. (2000) · Neuron · doi:10.1016/s0896-6273(00)81064-8 · Cited by 308
Tallini, G., Santoro, M. M., Helie, M., Carlomagno, F., Salvatore, G., Chiappetta, G., Carcangiu, M. L., & Fusco, A. (1998) · PubMed · Cited by 302
Yoh, K., Seto, T., Satouchi, M., Nishio, M., Yamamoto, N., Murakami, H., Nogami, N., Matsumoto, S., Kohno, T., Tsuta, K., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30322-8 · Cited by 294
Okamoto, K., Kodama, K., Takase, K., Sugi, N. H., Yamamoto, Y., Iwata, M., & Tsuruoka, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.007 · Cited by 288
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Kato, S., Subbiah, V., Marchlik, E., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1679 · Cited by 282
Elisei, R., Romei, C., Vorontsova, T., Cosci, B., Veremeychik, V., Kuchinskaya, E., Basolo, F., Demidchik, E. P., Miccoli, P., Pinchera, A., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.7.7678 · Cited by 275
Drilon, A., Wang, L., Arcila, M. E., Balasubramanian, S., Greenbowe, J. R., Ross, J. S., Stephens, P., Lipson, D., Miller, V. A., Kris, M. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2683 · Cited by 274
The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
Powell, D. J., Russell, J. P., Nibu, K., Li, G., Rhee, E. N., Liao, M., Goldstein, M., Keane, W. M., Santoro, M. M., Fusco, A., et al. (1998) · PubMed · Cited by 255
Besset, V., Scott, R. P., & Ibáñez, C. F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006908200 · Cited by 255
Lee, S.-H., Lee, J.-K., Ahn, M.-J., Kim, D.-W., Sun, J.-M., Keam, B., Kim, T. M., Heo, D. S., Ahn, J. S., Choi, Y.-L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw559 · Cited by 244
Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers
Ricarte-Filho, J. C., Li, S., Garcia-Rendueles, M. E. R., Montero-Conde, C., Voza, F., Knauf, J. A., Heguy, A., Viale, A., Bogdanova, T., Thomas, G. A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69766 · Cited by 241
Tozlu, S., Girault, I., Vacher, S., Vendrell, J., Andrieu, C., Spyratos, F., Cohen, P., Lidereau, R., & Bieche, I. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01120 · Cited by 238
Fenton, C. L., Lukes, Y., Nicholson, D., Dinauer, C. A., Francis, G. L., & Tuttle, R. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6472 · Cited by 225
Segouffin-Cariou, C., & Billaud, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3568 · Cited by 223
Hayashi, H., Ichihara, M., Iwashita, T., Murakami, H., Shimono, Y., Kawai, K., Kurokawa, K., Murakumo, Y., Imai, T., Funahashi, H., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203799 · Cited by 223
Ichihara, M. (2004) · Cancer Letters · doi:10.1016/s0304-3835(03)00456-7 · Cited by 197
Levin, J. Z., Berger, M. F., Adiconis, X., Rogov, P., Melnikov, A., Fennell, T., Nusbaum, C., Garraway, L. A., & Gnirke, A. (2009) · Genome Biology · doi:10.1186/gb-2009-10-10-r115 · Cited by 195
Fenton, C. L. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.3.1170 · Cited by 190
Structure and Physiology of the RET Receptor Tyrosine Kinase
Ibanez, C. F. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009134 · Cited by 183
Cheung, C. C. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.5.2187 · Cited by 180
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma
Romei, C., & Elisei, R. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00054 · Cited by 176
Critical and distinct roles for key RET tyrosine docking sites in renal development
Jain, S., Encinas, M., Johnson, E. M., & Milbrandt, J. (2006) · Genes & Development · doi:10.1101/gad.1387206 · Cited by 165
Alectinib Shows Potent Antitumor Activity against RET -Rearranged Non–Small Cell Lung Cancer
Kodama, T., Tsukaguchi, T., Satoh, Y., Yoshida, M., Watanabe, Y., Kondoh, O., & Sakamoto, H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0274 · Cited by 162
Hamatani, K., Eguchi, H., Ito, R., Mukai, M., Takahashi, K., Taga, M., Imai, K., Cologne, J., Soda, M., Arihiro, K., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0293 · Cited by 160
Romei, C., Ciampi, R., Faviana, P., Agate, L., Molinaro, E., Bottici, V., Basolo, F., Miccoli, P., Pacini, F., Pinchera, A., et al. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0130 · Cited by 160
Pekar‐Zlotin, M., Hirsch, F. R., Soussan‐Gutman, L., Ilouze, M., Dvir, A., Boyle, T. A., Wynes, M. W., Miller, V. A., Lipson, D., Palmer, G. A., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0389 · Cited by 151
Plaza-Menacho, I., Morandi, A., Robertson, D. M., Pancholi, S., Drury, S., Dowsett, M., Martin, L.-A., & Isacke, C. M. (2010) · Oncogene · doi:10.1038/onc.2010.209 · Cited by 149
Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
Offin, M. D., Guo, R., Wu, S. L., Sabari, J. K., Land, J. D., Ni, A., Montecalvo, J., Halpenny, D. F., Buie, L. W., Pak, T., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00386 · Cited by 130
RET rearrangements are actionable alterations in breast cancer
Paratala, B., Chung, J., Williams, C. B., Yilmazel, B., Petrosky, W., Williams, K. A., Schrock, A. B., Gay, L. M., Lee, E. C., Dolfi, S. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07341-4 · Cited by 129
Coordinated Activation of Autophosphorylation Sites in the RET Receptor Tyrosine Kinase
Coulpier, M., Anders, J., & Ibáñez, C. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107992200 · Cited by 128
Boulay, A., Breuleux, M., Stephan, C., Fux, C., Brisken, C., Fiche, M., Wartmann, M., Stumm, M., Lane, H. A., & Hynes, N. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5100 · Cited by 123
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
Drilon, A. E. D. C., Bergagnini, I., Delasos, L., Sabari, J. K., Woo, K. M., Plodkowski, A. J., Wang, L., Hellmann, M. D., Joubert, P., Sima, C. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw163 · Cited by 121
Morandi, A., Martin, L., Gao, Q., Pancholi, S., Mackay, A. G., Robertson, D. M., Zvelebil, M., Dowsett, M., Plaza-Menacho, I., & Isacke, C. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4265 · Cited by 120
Score, J., Curtis, C., Waghorn, K., Stalder, M., Jotterand, M., Grand, F., & Cross, N. C. P. (2006) · Leukemia · doi:10.1038/sj.leu.2404154 · Cited by 117
Leeman‐Neill, R. J., Brenner, A. V., Little, M. P., et al. (2013) · Cancer · doi:10.1002/cncr.27893 · Cited by 116
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers
Roskoski, R. J., & Sadeghi‐Nejad, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.021 · Cited by 114
Identification and characterization of RET fusions in advanced colorectal cancer
Rolle, A.-F. L., Klempner, S. J., Garrett, C. R., Seery, T. E., Sanford, E. M., Balasubramanian, S., Ross, J. S., Stephens, P. J., Miller, V. A., Ali, S. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4325 · Cited by 113
Carlomagno, F., Vitagliano, D., Guida, T., Basolo, F., Castellone, M. D., Melillo, R. M., Fusco, A., & Santoro, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021278 · Cited by 113
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Drilon, A. E. D. C., Fu, S., Patel, M. R., Fakih, M., Wang, D., Olszanski, A. J., Morgensztern, D., Liu, S. V., Cho, B. C., Bazhenova, L. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0839 · Cited by 112
Gainor, J. F., Lee, K. H., Curigliano, G., Doebele, R. C., Kim, D., Baik, C. S., Tan, D. S.-W., Junior, G. L. L., Gadgeel, S. M., Cassier, P. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9008 · Cited by 112
Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma
Musholt, T. J., Musholt, P. B., Khaladj, N., Schulz, D., Scheumann, G. F. W., & Klempnauer, J. (2000) · Surgery · doi:10.1067/msy.2000.110845 · Cited by 109
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
Pietrantonio, F., Nicolantonio, F. D., Schrock, A. B., Lee, J., Morano, F., Fucà, G., Nikolinakos, P. G., Drilon, A. E. D. C., Hechtman, J. F., Christiansen, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy090 · Cited by 108
RET is a potential tumor suppressor gene in colorectal cancer
Luo, Y., Tsuchiya, K. D., Park, D. I., Fausel, R. A., Kanngurn, S., Welcsh, P. L., Dzieciatkowski, S., Wang, J., & Grady, W. M. (2012) · Oncogene · doi:10.1038/onc.2012.225 · Cited by 102
Vita, G. D., Melillo, R. M., Carlomagno, F., Visconti, R., Castellone, M. D., Bellacosa, A., Billaud, M., Fusco, A., Tsichlis, P. N., & Santoro, M. M. (2000) · PubMed · Cited by 96
Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad
Matsubara, D., Kanai, Y., Ishikawa, S., Ohara, S., Yoshimoto, T., Sakatani, T., Oguni, S., Tamura, T., Kataoka, H., Endo, S., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182721ed1 · Cited by 96
Oncogene profile of papillary thyroid carcinoma
Sugg, S. L., Ezzat, S., Zheng, L., Freeman, J. L., Rosen, I. B., & Asa, S. L. (1999) · Surgery · doi:10.1016/s0039-6060(99)70287-4 · Cited by 93
Gattelli, A., Nalvarte, I., Boulay, A., Roloff, T. C., Schreiber, M., Carragher, N. O., Macleod, K., Schlederer, M., Lienhard, S., Kenner, L., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302625 · Cited by 92
Jijiwa, M., Kawai, K., Fukihara, J., Nakamura, A., Hasegawa, M., Suzuki, C., Sato, T., Enomoto, A., Asai, N., Murakumo, Y., et al. (2008) · Genes to Cells · doi:10.1111/j.1365-2443.2008.01171.x · Cited by 91
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years
Romei, C., Fugazzola, L., Puxeddu, E., Frasca, F., Viola, D., Muzza, M., Moretti, S., Nicolosi, M. L., Giani, C., Cirello, V., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1269 · Cited by 90
Klempner, S. J., Bazhenova, L. A., Braiteh, F. S., Nikolinakos, P. G., Gowen, K. A., Cervantes, C. M., Chmielecki, J., Greenbowe, J. R., Ross, J. S., Stephens, P. J., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.021 · Cited by 89
Ito, Y., Okada, Y., Sato, M., Sawai, H., Funahashi, H., Murase, T., Hayakawa, T., & Manabe, T. (2005) · Surgery · doi:10.1016/j.surg.2005.07.007 · Cited by 89
Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA
Supplee, J., Milan, M. S. D., Lim, L. P., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.004 · Cited by 84
Rich, T. A., Reckamp, K. L., Chae, Y. K., Doebele, R. C., Iams, W. T., Oh, M. S., Raymond, V. M., Lanman, R. B., Riess, J. W., Stinchcombe, T. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4049 · Cited by 83
Nelson-Taylor, S. K., Le, A. T., Yoo, M., Schubert, L., Mishall, K. M., Doak, A. E., Varella‐Garcia, M., Tan, A. C., & Doebele, R. C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0008 · Cited by 80
Li, F., Feng, Y., Fang, R., Fang, Z., Xia, J., Han, X., Liu, X., Chen, H., Liu, H., & Ji, H. (2012) · Cell Research · doi:10.1038/cr.2012.27 · Cited by 79
A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing
Beadling, C., Wald, A. I., Warrick, A., Neff, T. L., Zhong, S., Nikiforov, Y. E., Corless, C. L., & Nikiforova, M. N. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.10.002 · Cited by 78
Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors
Reeser, J. W., Patacsil, D., Miya, J., Kautto, E. A., Lyon, E., Zhu, E. Y., Wing, M. R., Smith, A. M., Reeder, M., Samorodnitsky, E., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2017.05.006 · Cited by 78
Wang, X. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.10.008 · Cited by 75
Detection of Gene Rearrangements in Targeted Clinical Next-Generation Sequencing
Abel, H., Al‐Kateb, H., Cottrell, C. E., Bredemeyer, A. J., Pritchard, C. C., Grossmann, A. H., Wallander, M. L., Pfeifer, J. D., Lockwood, C. M., & Duncavage, E. J. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.03.006 · Cited by 72
Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations
Li, G. G., Somwar, R., Joseph, J. D., Smith, R. S., Hayashi, T., Martin, L., Franovic, A., Schairer, A., Martin, E. S., Riely, G. J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1887 · Cited by 67
Basolo, F., Molinaro, E., Agate, L., Pinchera, A., Pollina, L., Chiappetta, G., Monaco, C., Santoro, M., Fusco, A., Miccoli, P., et al. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450599 · Cited by 58
Drosophila Cancer Models Identify Functional Differences between Ret Fusions
Levinson, S., & Cagan, R. L. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.019 · Cited by 58
Andersson, E., Arvidsson, Y., Swärd, C., Hofving, T., Wängberg, B., Kristiansson, E., & Nilsson, O. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.48 · Cited by 57
Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma
Go, H., Jung, Y. J., Kang, H. W., Park, I. K., Kang, C. H., Lee, J. W., Ju, Y. S., Seo, J., Chung, D. H., & Kim, Y. T. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.009 · Cited by 56
Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma
Amit, M., Na’ara, S., Leider–Trejo, L., Binenbaum, Y., Kulish, N., Fridman, E., Shabtai-Orbach, A., Wong, R. J., & Gil, Z. (2017) · Oncogene · doi:10.1038/onc.2016.483 · Cited by 56
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer
Horiike, A., Takeuchi, K., Uenami, T., Kawano, Y., Tanimoto, A., Kaburaki, K., Tambo, Y., Kudo, K., Yanagitani, N., Ohyanagi, F., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.12.011 · Cited by 55
Lin, C., Wang, S., Xie, W., Chang, J., & Gan, Y. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1046649 · Cited by 54
RET Signaling in Prostate Cancer
Ban, K., Feng, S., Shao, L., & Ittmann, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0528 · Cited by 49
Spanheimer, P. M., Park, J. M., Askeland, R. W., Kulak, M. V., Woodfield, G. W., Andrade, J. P. D., Cyr, A. R., Sugg, S. L., Thomas, A., & Weigel, R. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2221 · Cited by 48
Vandetanib as a potential new treatment for estrogen receptor‐negative breast cancers
Hatem, R., Labiod, D., Château‐Joubert, S., de Plater, L., Botty, R. E., Vacher, S., Bonin, F., Servely, J., Dieras, V. C., Bièche, I., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29974 · Cited by 45
Lu, Z., Zhang, Y., Feng, D., Sheng, J., Yang, W., & Liu, B. (2017) · Oncotarget · doi:10.18632/oncotarget.17412 · Cited by 43
Clinical tumour sequencing for precision oncology: time for a universal strategy
Cheng, M. L., Berger, M. F., Hyman, D. M., & Solit, D. B. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0043-2 · Cited by 42
Taylor, M. H., Gainor, J. F., Hu, M. I.-N., Zhu, V. W., Junior, G. L. L., Leboulleux, S., Brose, M. S., Schüler, M., Bowles, D. W., Kim, D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.6018 · Cited by 42
Puxeddu, E., Moretti, S., Giannico, A., Martinelli, M., Marino, C., Avenia, N., Cristofani, R., Farabi, R., Reboldi, G., Ribacchi, R., et al. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480505 · Cited by 41
EGF Induced RET Inhibitor Resistance inCCDC6-RETLung Cancer Cells
Chang, H. K., Sung, J. H., Moon, S. U., Kim, H.-S., Kim, J. W., & Lee, J. S. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.1.9 · Cited by 41
Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation
Jeong, W., Mo, J., Park, M. W., Choi, I. J., An, S.-Y., Jeon, E.-H., & Ahn, S. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.5.16303 · Cited by 37
RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients
Sarfaty, M., Moore, A., Neiman, V., Dudnik, E., Ilouze, M., Gottfried, M., Katznelson, R., Nechushtan, H., Sorotsky, H. G., Paz, K., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.09.003 · Cited by 36
Andreucci, E., Francica, P., Fearns, A., Martin, L., Chiarugi, P., Isacke, C. M., & Morandi, A. (2016) · Oncotarget · doi:10.18632/oncotarget.11826 · Cited by 33
Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma
Zafon, C., Obiols, G., Castellví, J., Tallada, N., Baena, J. A., Simó, R., & Mesa, J. (2007) · Histopathology · doi:10.1111/j.1365-2559.2006.02555.x · Cited by 31
Moskalev, E. A., Frohnauer, J., Merkelbach‐Bruse, S., Schildhaus, H., Dimmler, A. W., Schubert, T., Boltze, C., König, H., Fuchs, F. S., Sı̂rbu, H., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.03.002 · Cited by 28
Registrational results of LOXO-292 in patients with RET-altered thyroid cancers
Wirth, L. J., Sherman, E. J., Drilon, A. E. D. C., Solomon, B., Robinson, B. G., Lorch, J. H., McCoach, C. E., Patel, J. D., Leboulleux, S., Worden, F. P., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.093 · Cited by 27
Oliveira, D. M., Grillone, K., Mignogna, C., Falco, V. D., Laudanna, C., Biamonte, F., Locane, R., Corcione, F., Fabozzi, M., Sacco, R., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0746-y · Cited by 26
RET Rearrangements in Lung Adenocarcinoma and Radiation
Đačić, S., Luvison, A., Evdokimova, V. N., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000015 · Cited by 24
Novel targeted therapeutics for MEN2
Redaelli, S., Plaza-Menacho, I., & Mologni, L. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0297 · Cited by 20
Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol
Takeuchi, S., Murayama, T., Yoshimura, K., Kawakami, T., Takahara, S., Imai, Y., Kuribayashi, Y., Nagase, K., Goto, K., Nishio, M., et al. (2017) · The Journal of Medical Investigation · doi:10.2152/jmi.64.317 · Cited by 17
RET Mutations in Neuroendocrine Tumors: Including Small-Cell Lung Cancer
Rudin, C. M., Drilon, A. E. D. C., & Poirier, J. T. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000301 · Cited by 16
Ali, S. M., Ou, S. I., He, J., Peled, N., Chmielecki, J., Pinder, M. C., Palma, N. A., Akerley, W., Wang, K., Molina, J. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8049 · Cited by 16
RET Fusion Genes in Korean Non-Small Cell Lung Cancer
Yoo, S. S., Jin, G., Jung, H. J., Hong, M. J., Choi, J. E., Jeon, H., Lee, S. Y., Lim, J. O., & Park, J. Y. (2013) · Journal of Korean Medical Science · doi:10.3346/jkms.2013.28.10.1555 · Cited by 11
Mishra, A., Agrawal, V., Krishnani, N., & Mishra, S. (2009) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.57390 · Cited by 9
Destabilizing RET in targeted treatment of thyroid cancers
Gild, M. L., Bullock, M., Pon, C. K., Robinson, B. G., & Clifton-Bligh, R. J. (2015) · Endocrine Connections · doi:10.1530/ec-15-0098 · Cited by 7
Cited by
Recent advances in non-small cell lung cancer targeted therapy; an update review
Araghi, M., Mannani, R., Heidarnejad maleki, A., Hamidi, A., Rostami, S., Safa, S. H., Faramarzi, F., Khorasani, S., Alimohammadi, M., Tahmasebi, S., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02990-y · Cited by 328
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Metadata
- Authors
- Li, A. Y., McCusker, M. G., Russo, A., Scilla, K. A., Gittens, A., Arensmeyer, K., Mehra, R., Adamo, V., & Rolfo, C.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 81
- Pages
- 101911
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W2982397907
- Cited by
- 257
- References
- 119
- FWCI
- 18.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.